坦洛新联合左归丸治疗慢性前列腺伴性功能障碍临床疗效分析

The clinical effect and analysis about Tamsulosin combining Zuogui Wan on treating chronic prostatitis related sexual dysfunction

目的研究坦洛新联合左归丸治疗慢性前列腺炎伴性功能障碍的临床疗效.方法：选取2012 年2 月到2014 年2 月期间我院收治的112 例前列腺炎伴性功能障碍的患者作为研究对象,将所有患者随机分为两组,对照组患者服用坦洛新,观察组患者在口服坦洛新的基础上联合应用左归丸,比较两种治疗的临床效果.结果：对照组7 名（12.50%）患者发生不良反应,观察组8 名（14.29%）患者发生不良反应,二者无统计学差异（P〉0.05）,患者经过调整坦洛新用量后好转.经过治疗后,患者的评分结果较治疗前明显好转（P〈0.05）;治疗后两组患者的NIH-CPSI 和IIEF-5 评分有统计学差异（P〈0.05）.对照组治疗有效率62.50%（35/56）,观察组92.86%（52/56）,二者具有统计学差异（P〈0.05）.讨论：洛坦新联合左归丸治疗慢性前列腺炎合并性功能障碍临床疗效明显,不会增加患者不良反应的发生,值得在临床上推广应用.

objective to research the clinical effect about Tamsulosin combining Zuogui Wan on treating chronic prostatitis related sexual dysfunction. Method： Choose 112cases with prostate associated with sexual dysfunction who were accepted by our hospital during February, 2012 and February, 2014 as research subjects in prospective studies. Theywere equally and randomly divided into contrast group and observe group. Patients in the contrast group took Tamsulosin orally while patients in the observe group combined withZuogui Wan on the basis of taking Tamsulosin orally. Then contrast the clinical effect of the two groups. Result： 7 patients in contrast group（12.50%）have adverse reaction. 8cases in observe group（14.29%）have adverse reaction. The result has no statistical significance（P〉0.05）. But after changing Tamsulosin dosage, it becomes better. Aftertreating, comparing with pre-treating, patients’ scores become better （P〈0.05）. The score of NIH-CPSI and IIEF-5 of two groups after treating have statistical significance（P〈0.05）.The therapeutic efficiency ratio in contrast group is 62.50%（35/56）. The therapeutic efficiency ratio in observe group is 92.86%（52/56）. The result posess statisticalsignificance（P〈0.05）. Conclusion： the effect of Tamsulosin combining Zuogui Wan on treating chronic prostatitis related sexual dysfunction is obviously. The occourance ofpatients’ adverse reaction cannot take place. It is valuable to be widely applied in clinic.